WHO says it is analyzing two new Omicron COVID sub-variants

Viruses mutate all the time but only some mutations affect their ability to spread or evade prior immunity from vaccination or infection, or the severity of disease they cause.

 The COVID-19 vaccine (illustrative). (photo credit: PIXABAY)
The COVID-19 vaccine (illustrative).
(photo credit: PIXABAY)

The World Health Organization said on Monday it is tracking a few dozen cases of two new sub-variants of the highly transmissible Omicron strain of the coronavirus to assess whether they are more infectious or dangerous.

It has added BA.4 and BA.5, sister variants of the original BA.1 Omicron variant, to its list for monitoring. It is already tracking BA.1 and BA.2 - now globally dominant - as well as BA.1.1 and BA.3.

The WHO said it had begun tracking them because of their "additional mutations that need to be further studied to understand their impact on immune escape potential."

Viruses mutate all the time but only some mutations affect their ability to spread or evade prior immunity from vaccination or infection, or the severity of disease they cause.

For instance, BA.2 now represents nearly 94% of all sequenced cases and is more transmissible than its siblings, but the evidence so far suggests it is no more likely to cause severe disease.

 Test tubes labelled ''COVID-19 Omicron variant test positive'' are seen in this illustration picture taken January 15, 2022.  (credit: REUTERS/DADO RUVIC/ILLUSTRATION) Test tubes labelled ''COVID-19 Omicron variant test positive'' are seen in this illustration picture taken January 15, 2022. (credit: REUTERS/DADO RUVIC/ILLUSTRATION)

Only a few dozen cases of BA.4 and BA.5 have been reported to the global GISAID database, according to WHO.

The UK's Health Security Agency said last week BA.4 had been found in South Africa, Denmark, Botswana, Scotland, and England from Jan. 10 to March 30.

All the BA.5 cases were in South Africa as of last week, but on Monday Botswana's health ministry said it had identified four cases of BA.4 and BA.5, all among people aged 30 to 50 who were fully vaccinated and experiencing mild symptoms.